Cannabidiol for ASD Open Trial

NCT03900923 | Completed Phase 2 Results DMC FDA Drug

• 1 other identifier: 18-00250
• Study Type: interventional
• Target: 29
• Locations: 1 country
• Sites: 1

Brief Summary

This is a 6-week open trial to identify the optimal dosing of cannabidiol (CBD) in youth with autism spectrum disorder (ASD) and to identify primary and secondary outcomes for future controlled studies. This study evaluates change in symptoms commonly associated with ASD, as evidence suggests that CBD may be effective in addressing difficulties such as irritability and anxiety, while maintaining a benign adverse effect (AE) profile in children and adolescents. 30 male and female participants with ASD between the ages of 7 and 17 years old are being recruited. Participants have fluent speech and an estimated IQ greater than or equal to 80. Study intervention is 98% pure CBD. The CBD is Greenwich Biosciences, Inc.'s 100mg/mL oral solution, brand name EPIDIOLEX. First, a Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design ended after the fifth cohort of participants, and the two lower doses, 3 and 6 mg/kg/day, were eliminated. The highest dose, 9 mg/kg/day, was not tested. Therefore, in subsequent cohorts, we will be examining 9 mg/kg/day exclusively in up to 15 additional participants with co-occurring ASD and attention-deficit/hyperactivity disorder (ADHD) diagnoses, as this clinical profile appears to most closely resemble youth classified as responders within the BOIN design.

Conditions

ASD; Autism Spectrum Disorder

Keywords

cannabidiol (CBD)

Outcome Measures

Primary Outcomes (1)

• Clinical Global Impression Scale-Improvement (CGI-I)

  The physician-rated CGI-I comprises one question asking how much a participant's condition has changed since baseline. The item is answered using a 7-point Likert scale, where 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. The total score is the item response; lower scores indicate greater improvement.

  Week 6

Secondary Outcomes (15)

• Change in Repetitive Behavior Scale-Revised (RBS-R) Score

  Baseline, Week 6

• Change in Social Responsiveness Scale, 2nd Edition (SRS-2), School-Age Form Score

  Baseline, Week 6

• Change in Aberrant Behavior Checklist (ABC) - Irritability Subscale Score

  Baseline, Week 6

• Change in Screen for Child Anxiety Related Disorders (SCARED), Parent Version Score

  Baseline, Week 6

• Change in Sleep Disturbance Scale for Children (SDSC) Score

  Baseline, Week 6

Study Arms (1)

98% pure CBD

EXPERIMENTAL

98% pure CBD. The CBD will be 100mg/mL oral solution provided by Greenwich Biosciences, Inc.

Drug: 98% pure CBD

Interventions

98% pure CBD DRUG

A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.

98% pure CBD

Eligibility Criteria

• Age: 7 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Male or female pediatric outpatients aged between and including 7 to 17.9 years old
• Diagnosis of ASD confirmed by the ADOS-2 and DSM-5 criteria
• Diagnosis of ADHD confirmed by clinician review of K-SADS-COMP and DSM-5 Criteria
• SRS-2 Total T-score of 66 or higher
• CGI-S score of 4 or higher
• Physical exam and laboratory results that are within normal range for their age
• Fluent speech
• Estimated IQ of at least 80
• Presence of a parent/legal guardian who is able to consent for their participation and complete assessments regarding the child's development and behavior throughout the study

You may not qualify if:

• History or current evidence of significantly impaired liver function, defined as 1) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 5 × upper limit of normal (ULN); 2) ALT or AST \> 3 × ULN with concomitant total bilirubin \> 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia
• History of active seizure disorder or epilepsy; patients seizure free for \>5 years off of antiepileptic drugs and other than uncomplicated febrile seizures are not excluded
• Exposure to any investigational agent in the 30 days prior to initiation of trial
• Treatment with CBD or other cannabinoid within the previous two months
• Current use of medications metabolized primarily by CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, or CYP2D6 isoenzymes. Methylphenidate is not contraindicated.
• History of drug abuse including marijuana/cannabis use in the past 3 months
• Positive urine sample results from drug screening indicating presence of the following drugs: THC, opiates, methamphetamine, or cocaine
• Diagnosis of a known genetic disorder (e.g., Prader-Willi Syndrome, Angelman Syndrome, etc.).
• Active suicidality (ideation and plan) is present
• A current psychiatric diagnosis of bipolar disorder, major depressive disorder (MDD), psychosis, schizophrenia, or post-traumatic stress disorder (PTSD)
• Pregnant or lactating patients or patients who will not agree to be abstinent or use contraception
• A medical condition that severely impacts the subject's ability to participate in the study, interferes with the conduct of the study, confounds interpretation of study results or endangers the subject's well-being
• Diagnosis of Rett Syndrome or Childhood Disintegrative Disorder or marked sensory impairment such as deafness or blindness
• Subjects who have had changes in allied health therapies, behavioral or educational interventions within 4 weeks prior to initiation of trial, other than those associated with school holidays

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders

Results Point of Contact

• Title: Francisco X Castellanos, MD
• Organization: NYU Langone Health

Francisco.Castellanos@nyulangone.org

646-754-5194

Study Officials

• Francisco X Castellanos, MD

  New York Langone Health

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2019
• First Posted: April 3, 2019
• Study Start: March 12, 2019
• Primary Completion: May 4, 2023
• Study Completion: May 4, 2023
• Last Updated: May 31, 2024
• Results First Posted: May 31, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in the investigator's University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting requests and accessing data may be found at (Link to be provided).
• Access Criteria: Data will be available for any purpose.

Locations

US (1)